Pharmacological antithrombotic adjuncts to percutaneous coronary intervention

Authors: Lucking, Andrew J¹; Newby, David E²

Source: Expert Opinion on Pharmacotherapy, Volume 8, Number 6, April 2007 , pp. 759-776(18)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Stent thrombosis is the major cause of early adverse events during percutaneous coronary intervention. Its incidence has fallen considerably in recent years, principally due to the introduction of effective antithrombotic therapies. The selection of an appropriate antithrombotic regimen is critical in achieving a balance between reducing ischaemic events and minimising bleeding complications in patients undergoing percutaneous coronary intervention. In this article, evidence for the role of antiplatelet and anticoagulant therapies is discussed, including the thienopyridines, glycoprotein IIb/IIIa receptor antagonists, direct thrombin inhibitors and pentasaccharides.

Keywords: anticoagulation; antiplatelet treatment; percutaneous coronary intervention

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14656566.8.6.759

Affiliations: 1: 1Clinical Research Fellow, The University of Edinburgh, Room SU.305, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SU, Scotland., Email: andrew.lucking@btinternet.com 2: 2Professor of Cardiology, Edinburgh University, Centre for Cardiovascular Science, Edinburgh, Scotland

Publication date: 2007-04-01

More about this publication?